This strategy has been extensively investigated in Huntington’s disease to improve the non-allele-specific huntingtin (HTT)-lowering gapmer ASO tominersen, of which a phase III trial was stopped due to worsening clinical outcomes.51 The gene discussed is HTT; the disease is juvenile Huntington disease.